Medicare Secures Lower Drug Prices for 2027
The federal government recently revealed the outcomes of its Medicare drug price negotiations, with 15 medications set to be offered at lower prices in 2027.
Among the drugs included in the negotiation are Ozempic, Wegovy, and Rybelsus, which treat obesity and Type 2 diabetes. Medicare will receive a substantial 71% discount on these blockbuster drugs, which currently cost around a thousand dollars per month.
The negotiations also encompassed medications for conditions like asthma, breast cancer, leukemia, and Huntington’s disease, with discounts ranging from 38% to 85% on drugs like Austedo and Janumet.
Health and Human Services Secretary Robert F. Kennedy, Jr., stated, “President Trump directed us to stop at nothing to lower health care costs for the American people. As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors.”
The negotiation process was made possible by the Biden-era Inflation Reduction Act, which ended Medicare’s 20-year ban on negotiating drug prices. The Centers for Medicare and Medicaid Services estimate that implementing the new, lower prices in 2024 would have saved the program $12 billion.
Dr. Benjamin Rome, a health policy researcher, expressed optimism about the latest negotiated prices, highlighting the significant savings for taxpayers and patients. The drug selection criteria were based on specific factors, including lack of generic competition, high Medicare spending, and market presence.
Interestingly, a prior deal with Novo Nordisk set lower prices for Ozempic and Wegovy compared to the negotiated prices announced recently. Novo Nordisk has expressed a desire for clarity from CMS regarding pricing and coverage mechanisms.
Despite concerns about government price setting, the negotiated drug prices have been well-received by advocacy groups like AARP, who view the initiative as a positive step in lowering prescription costs for older Americans.
Overall, the announcement of reduced drug prices under Medicare for 2027 is a significant development that promises financial relief for millions of Medicare beneficiaries.
